Forte Biosciences Announces Promising Results from FB102 Celiac Disease Phase 1b Trial at Tampere Symposium

Reuters09-15

Forte Biosciences Announces Promising Results from FB102 Celiac Disease Phase 1b Trial at Tampere Symposium

Forte Biosciences, Inc. $(FBRX)$, a clinical-stage biopharmaceutical company, has announced the presentation of results from its FB102 Celiac Disease Trial at the Tampere Celiac Disease Symposium in Finland. The oral presentation highlighted the outcomes of a phase 1b study which demonstrated that FB102 effectively prevents histological damage and mitigates gluten challenge-induced symptoms in patients with celiac disease. Key findings included a significant decline in TCR γδ density in patients treated with FB102 compared to those on placebo, as well as a reduction in Ki67-positive intraepithelial cell density and a 95% decline in NK cells. These results suggest that FB102 may offer a differentiated therapeutic option for celiac disease. The phase 2 trial is currently underway, with topline data anticipated in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forte Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250915660032) on September 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2567140941?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-15 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567140941","market":"nz","top_or_hot":-1,"title":"Forte Biosciences Announces Promising Results from FB102 Celiac Disease Phase 1b Trial at Tampere Symposium","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Forte Biosciences Announces Promising Results from FB102 Celiac Disease Phase 1b Trial at Tampere Symposium\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Forte Biosciences, Inc. <a href=\"https://laohu8.com/S/FBRX\">$(FBRX)$</a>, a clinical-stage biopharmaceutical company, has announced the presentation of results from its FB102 Celiac Disease Trial at the Tampere Celiac Disease Symposium in Finland. The oral presentation highlighted the outcomes of a phase 1b study which demonstrated that FB102 effectively prevents histological damage and mitigates gluten challenge-induced symptoms in patients with celiac disease. Key findings included a significant decline in TCR γδ density in patients treated with FB102 compared to those on placebo, as well as a reduction in Ki67-positive intraepithelial cell density and a 95% decline in NK cells. These results suggest that FB102 may offer a differentiated therapeutic option for celiac disease. The phase 2 trial is currently underway, with topline data anticipated in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forte Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250915660032) on September 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences Announces Promising Results from FB102 Celiac Disease Phase 1b Trial at Tampere Symposium</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences Announces Promising Results from FB102 Celiac Disease Phase 1b Trial at Tampere Symposium\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-15 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Forte Biosciences Announces Promising Results from FB102 Celiac Disease Phase 1b Trial at Tampere Symposium\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Forte Biosciences, Inc. <a href=\"https://laohu8.com/S/FBRX\">$(FBRX)$</a>, a clinical-stage biopharmaceutical company, has announced the presentation of results from its FB102 Celiac Disease Trial at the Tampere Celiac Disease Symposium in Finland. The oral presentation highlighted the outcomes of a phase 1b study which demonstrated that FB102 effectively prevents histological damage and mitigates gluten challenge-induced symptoms in patients with celiac disease. Key findings included a significant decline in TCR γδ density in patients treated with FB102 compared to those on placebo, as well as a reduction in Ki67-positive intraepithelial cell density and a 95% decline in NK cells. These results suggest that FB102 may offer a differentiated therapeutic option for celiac disease. The phase 2 trial is currently underway, with topline data anticipated in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forte Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250915660032) on September 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL63rrPR:1","article_id":"2567140941","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567140941","pubTimestamp":1757941273,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Forte Biosciences, Inc. , a clinical-stage biopharmaceutical company, has announced the presentation of results from its FB102 Celiac Disease Trial at the Tampere Celiac Disease Symposium in Finland. The oral presentation highlighted the outcomes of a phase 1b study which demonstrated that FB102 effectively prevents histological damage and mitigates gluten challenge-induced symptoms in patients with celiac disease. Key findings included a significant decline in TCR γδ density in patients treated with FB102 compared to those on placebo, as well as a reduction in Ki67-positive intraepithelial cell density and a 95% decline in NK cells. These results suggest that FB102 may offer a differentiated therapeutic option for celiac disease. The phase 2 trial is currently underway, with topline data anticipated in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","FBRX":"Forte BioSciences Inc"},"translate_title":"Forte Biosciences在坦佩雷研讨会上宣布FB102乳糜泻1b期试验的有希望结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FBRX":0.9},"content_text":"Forte Biosciences Announces Promising Results from FB102 Celiac Disease Phase 1b Trial at Tampere Symposium\n    \n\n        Forte Biosciences, Inc. $(FBRX)$, a clinical-stage biopharmaceutical company, has announced the presentation of results from its FB102 Celiac Disease Trial at the Tampere Celiac Disease Symposium in Finland. The oral presentation highlighted the outcomes of a phase 1b study which demonstrated that FB102 effectively prevents histological damage and mitigates gluten challenge-induced symptoms in patients with celiac disease. Key findings included a significant decline in TCR γδ density in patients treated with FB102 compared to those on placebo, as well as a reduction in Ki67-positive intraepithelial cell density and a 95% decline in NK cells. These results suggest that FB102 may offer a differentiated therapeutic option for celiac disease. The phase 2 trial is currently underway, with topline data anticipated in 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forte Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250915660032) on September 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2567140941","isCrawlerRequest":true}